MenB vaccine offers men no protection from gonorrhoea, claims major study

MenB Vaccine's Efficacy in Combating Gonorrhoea Under Scrutiny

MenB vaccine offers men no protection from gonorrhoea, a major finding from a recent study published in the New England Journal of Medicine has sparked renewed debate about its role in preventing sexually transmitted infections. The vaccine, originally developed to target meningococcal disease in infants, was introduced in the UK in 2025 as part of a strategy to reduce gonorrhoea cases among men who have sex with men. However, new data from Australia suggests that its impact on gonorrhoea may be limited, challenging assumptions about its effectiveness.

Study Results Highlight No Significant Reduction in Gonorrhoea Cases

The GoGoVax trial, led by researchers at the University of New South Wales, investigated the vaccine’s role in preventing gonorrhoea. Over two years, 587 participants were divided into two groups: one received the MenB vaccine, and the other was given a placebo. Despite initial optimism, the study found that the vaccinated group experienced 291 new infections, compared to 285 in the placebo group, indicating no statistically significant difference in protection. This outcome contradicts earlier claims that the vaccine could reduce gonorrhoea rates by 38%.

"The study’s results align with two previous trials and collectively suggest that the MenB vaccine is not effective in preventing gonorrhoea," the research team stated. This conclusion has raised questions about the broader application of the vaccine for STI prevention and its potential role in public health campaigns.

UK Health Authorities Maintain Current Recommendations

UK Health Security Agency (UKHSA) officials have confirmed that they will not adjust their guidance on the MenB vaccine, citing the need for further research to confirm the findings. Dr. Mary Ramsay, a public health director at the agency, noted that the rollout of the vaccine has already reached over 30,000 individuals in England, providing valuable data on its real-world impact. "While this study questions its efficacy against gonorrhoea, the long-term effects of vaccination programs should still be monitored closely," she emphasized.

The study’s results could influence future strategies for STI prevention, particularly as antimicrobial resistance continues to rise. Gonorrhoea, which has been on the rise globally, now poses a significant challenge to healthcare systems, with cases in England remaining at record levels. The MenB vaccine’s potential as an STI preventative tool has been both celebrated and scrutinized, depending on the evidence presented.

Implications for Public Health and Prevention Strategies

Experts caution that the findings do not necessarily invalidate the MenB vaccine’s use but highlight the need for more targeted approaches in STI prevention. Dr. Odile Harrison from the University of Oxford’s Population Health Infectious Disease Epidemiology Unit described the results as "disappointing," yet acknowledged the importance of the vaccine in reducing meningococcal disease. "While it may not prevent gonorrhoea, its role in combating other infections should not be overlooked," she said.

"If the evidence shifts, the strategy must adapt," said Taku Mukiwa from the Terrence Higgins Trust. The organization has called for a reassessment of how the MenB vaccine is being used in STI prevention, advocating for a combination of condoms, regular testing, and alternative vaccines to address the high infection rates. The study underscores the urgency of finding new solutions to tackle gonorrhoea’s growing prevalence.

MenB Vaccine: A Mixed Bag of Results

The MenB vaccine’s effectiveness has been a topic of discussion since its introduction. While it has been successful in reducing meningococcal disease in young children, its application to STI prevention has faced challenges. The latest Australian trial adds to the body of evidence questioning its impact on gonorrhoea, though the vaccine may still offer protection against other strains of Neisseria bacteria. This ambiguity has led to calls for more research and clearer guidelines on its use in sexual health programs.

Public health officials in the UK have expressed confidence in the MenB vaccine’s broader benefits, even if its specific efficacy against gonorrhoea remains uncertain. "The vaccine’s ability to prevent meningitis is well-established, and its role in reducing STI transmission is still being explored," Dr. Ramsay explained. As the study’s findings are reviewed, the MenB vaccine may continue to play a part in sexual health initiatives, even if its primary focus shifts away from gonorrhoea.

Broader Context of STI Prevention and Global Trends

The MenB vaccine’s role in STI prevention reflects a growing trend to repurpose vaccines for sexual health. However, the latest study highlights the complexities of such efforts. With gonorrhoea cases in England and other parts of the world remaining stubbornly high, the need for effective vaccines is more pressing than ever. While the MenB vaccine may not be the solution, it has sparked important discussions about the future of STI prevention and the role of immunization in combating antibiotic-resistant infections.